Thursday, September 03, 2020 10:07:55 AM
Vaccines only required to be 50% effective
when this winds down elderly and those with Comorbitity's
will line up 1st many healthy people will not be lining up.
This will not play out as planned.
when this winds down elderly and those with Comorbitity's
will line up 1st many healthy people will not be lining up.
This will not play out as planned.
Recent MRNA News
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/16/2026 08:32:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/16/2026 08:31:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/16/2026 08:31:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:21:25 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Moderna Resolves Global Patent Litigation with Arbutus/Genevant • ACCESS Newswire • 03/03/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:04:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 02:56:47 PM
- European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 02/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:49:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 03:26:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/20/2026 09:03:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2026 09:02:04 PM
- Moderna to Present at Upcoming Conferences in March 2026 • ACCESS Newswire • 02/19/2026 12:00:00 PM
- Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission • ACCESS Newswire • 02/18/2026 12:00:00 PM
- Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE • ACCESS Newswire • 02/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:41:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 12:02:14 PM
- Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates • ACCESS Newswire • 02/13/2026 12:00:00 PM
